Skip to search formSkip to main contentSkip to account menu

PI3Kdelta Inhibitor INCB040093

Known as: INCB040093 
An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell…
8520 Background: Inhibiting the PI3K or JAK-STAT pathways may be therapeutic in B-cell malignancies due to their contribution to… 
2015
2015
A phase 2 trial of INCB040093 alone or in combination with INCB039110 in patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
TPS8607 Background: In vitro data suggest that both the PI3K and JAK-STAT pathways contribute to tumor growth and survival in HL… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)